Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Blood (2024) 144 (Supplement 1): 891.

https://doi.org/10.1182/blood-2024-205077

Published: 2024

Journal Articles

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather J. Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schönland, Ashutosh Wechalekar, Jeffrey A. Zonder, Giovanni Palladini, Jackie Walling, Spencer Guthrie, Christie Nie, Carol Karp, Yuying Jin, Gene G. Kinney, Giampaolo Merlini

Blood (2023) 142 (14): 1208–1218.

https://doi.org/10.1182/blood.2022019406

Published: 2023

Includes: Supplemental data

Journal Articles

Pattern of Use and Outcomes of Daratumumab Therapy in Patients with Multiple Myeloma in a Real-World Setting: A Single Institution Experience

Danai Dima, MD, Xiao Hu, MD MPH, Joshua Dower, MD, Raymond L. Comenzo, MD, Cindy Varga, MDBSc

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-139741

Published: 2020

Journal Articles

Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience

Danai Dima, MD, Xiao Hu, MD MPH, Joshua Dower, MD, Raymond L. Comenzo, MD, Cindy Varga, MDBSc

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139643

Published: 2020

Journal Articles

Outcomes of Patients with Multiple Myeloma Harboring Gain/Amplification 1q in the Era of Modern Therapy

Xiao Hu, MD MPH, Cherng-Horng Wu, MD, Janet Cowan, PhD, Raymond L. Comenzo, MD, Cindy Varga, MDBSc

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-139780

Published: 2020

Journal Articles

Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda

Ashutosh D. Wechalekar, MD, Giovanni Palladini, MD PhD, Giampaolo Merlini, MD, Raymond L. Comenzo, MD, Arnaud Jaccard, MD PhD, NamPhuong Tran, MD, Huiling Pei, PhD, Sandra Y. Vasey, MSc, Brenda Tromp, MSc, Brendan M. Weiss, MD, Jessica Vermeulen, MD PhD, Efstathios Kastritis, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140514

Published: 2020

Journal Articles

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Blood (2020) 136 (Supplement 1): 48–50.

https://doi.org/10.1182/blood-2020-137582

Published: 2020

Journal Articles

Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda

Monique C. Minnema, Angela Dispenzieri, MD, Giampaolo Merlini, MD, Raymond L. Comenzo, MD, Efstathios Kastritis, MD, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM, Martha Grogan, MD, Ronald Witteles, MD, Frederick L. Ruberg, MD, Mathew S. Maurer, MD, NamPhuong Tran, MD, Xiang Qin, MD PhD, Sandra Y. Vasey, MSc, Brenda Tromp, MSc, Brendan M. Weiss, MD, Jessica Vermeulen, MD PhD, Arnaud Jaccard, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139754

Published: 2020

Journal Articles

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-136150

Published: 2020

Journal Articles

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Blood (2020) 136 (Supplement 1): 37–40.

https://doi.org/10.1182/blood-2020-139438

Published: 2020

Journal Articles

Therapeutic Activity of Combining BCL-2 and HMG-CoA Reductase Inhibition in Systemic Light-Chain Amyloidosis

Ping Zhou, MDPhD, Hashim Mann, MD, Xun Ma, DMD, MSc, PhD, Teresa Fogaren, NP, Yifei Zhang, MD, Denis Toskic, BS, Chakra P Chaulagain, MD, Cindy Varga, MDBSc, Raymond L. Comenzo, MD, Amandeep Godara, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-142656

Published: 2020

Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Blood (2020) 136 (1): 71–80.

https://doi.org/10.1182/blood.2019004460

Published: 2020

Includes: Supplemental data

Journal Articles

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Angela Dispenzieri, MD, Eftathios Kastritis, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM, Stefan O. Schönland, MD, Kihyun Kim, MD, Vaishali Sanchorawala, MD, Heather J Landau, MD, Fiona Kwok, FRACP,FRCPA,MBBS, Kenshi Suzuki, MD PhD, Raymond L Comenzo, MD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Douglas V. Faller, MD PhD, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 139.

https://doi.org/10.1182/blood-2019-124409

Published: 2019

Journal Articles

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Amandeep Godara, MD, Denis Toskic, BS, Benjamin Rosenthal, BS, Cindy Varga, MD BSc, Adin Kugelmass, BSc, Ping Zhou, MD PhD, Teresa Fogaren, NP, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 4369.

https://doi.org/10.1182/blood-2019-127004

Published: 2019

Journal Articles

B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase Inhibition

Amandeep Godara, MD, Ping Zhou, MD PhD, Benjamin Rosenthal, BS, Adin Kugelmass, BSc, Denis Toskic, BS, Teresa Fogaren, NP, Cindy Varga, MD BSc, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 4409.

https://doi.org/10.1182/blood-2019-126988

Published: 2019

Journal Articles

Monoclonal Gammopathies and Their Significance: A Retrospective Analysis of Monoclonal Gammopathy and Renal Disease

Anupama Kumar, MD, David Drew, MD, Leslie Inker, MD, Raymond L Comenzo, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 5498.

https://doi.org/10.1182/blood-2019-127618

Published: 2019

Journal Articles

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission but with Persistent Renal Disease

Cindy Varga, MD BSc, Viji Nair, PhD, Agnes Fogo, MD, Samih Nasr, MD, Bradley Godfrey, PhD, Felix Eichinge, PhD, Denis Toskic, BS, Matthias Kretzler, MD, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 5500.

https://doi.org/10.1182/blood-2019-123228

Published: 2019

Journal Articles

Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response

So Yeon Kim, MD, Amanda Vest, MD, Raymond L Comenzo, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 5502.

https://doi.org/10.1182/blood-2019-123890

Published: 2019

Journal Articles

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Morie A Gertz, MD, Adam D. Cohen, MD, Raymond L Comenzo, MD, Charles Du Mond, Eftathios Kastritis, Heather J Landau, MD, Edward N. Libby, III, MD, Michaela Liedtke, MD, Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Stefan O. Schönland, MD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Jeffrey A. Zonder, Gene Kinney, PhD

Blood (2019) 134 (Supplement_1): 3166.

https://doi.org/10.1182/blood-2019-124482

Published: 2019

Journal Articles

Senescent CD8+ T Cells in Myeloma Patients: Implications for Cellular Therapies

Lisa Xingguang Lee, MD, Denis Toskic, Xun Ma, DMD, MSc, PhD, Ping Zhou, MD PhD, Adin Kugelmass, BSc, Teresa Fogaren, NP, Raymond L Comenzo, MD

Blood (2018) 132 (Supplement 1): 5688.

https://doi.org/10.1182/blood-2018-99-118514

Published: 2018

NARROW

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Pattern of Use and Outcomes of Daratumumab Therapy in Patients with Multiple Myeloma in a Real-World Setting: A Single Institution Experience

Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience

Outcomes of Patients with Multiple Myeloma Harboring Gain/Amplification 1q in the Era of Modern Therapy

Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda

Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Therapeutic Activity of Combining BCL-2 and HMG-CoA Reductase Inhibition in Systemic Light-Chain Amyloidosis

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase Inhibition

Monoclonal Gammopathies and Their Significance: A Retrospective Analysis of Monoclonal Gammopathy and Renal Disease

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission but with Persistent Renal Disease

Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Senescent CD8+ T Cells in Myeloma Patients: Implications for Cellular Therapies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only